Apr 11, 2022 / 04:00PM GMT
Dror Harats - Vascular Biogenics Ltd. - CEO & Director
Good afternoon, everybody. And (foreign language). It is a great pleasure for me to open the VBL KOL event on ovarian cancer. And before we start, this is our safe harbor statement. There might be a forward-looking statement in today's events. And I want to note that opinion expressed by the KOLs are obviously their own. And now, I can really start.
So we have with us today 3 distinguished guests, all 3 are leading KOL in gyneco oncology in general and in ovarian cancer, in particular. All 3 have vast experience in drug development and bringing new molecules and therapies to their patients.
And I believe that being a doctor, especially in oncology, you have not just to take care of your patients, you have to make sure that you have the right drugs to treat your patients. And you have their short bio in front of you. So I will be really brief because we have a lot to talk today.
So ladies first. So we have Dr. Kathleen Moore from the University of Oklahoma; Dr. Moore is a member of our Steering Committee of the OVAL
Vascular Biogenics Ltd KOL Event on Ovarian Cancer Transcript
Apr 11, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers